Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.12
- Piotroski Score 1.00
- Grade Underweight
- Symbol (AVIR)
- Company Atea Pharmaceuticals, Inc.
- Price $3.32
- Changes Percentage (-0.9%)
- Change -$0.03
- Day Low $3.31
- Day High $3.43
- Year High $4.60
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $6.88
- High Stock Price Target $6.88
- Low Stock Price Target $6.88
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.95
- Trailing P/E Ratio -1.9
- Forward P/E Ratio -1.9
- P/E Growth -1.9
- Net Income $-135,956,000
Income Statement
Quarterly
Annual
Latest News of AVIR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...
The Phase 3 HCV trial design will address adherence issues with randomized trials and an active comparator. The company's plan aligns with FDA guidelines and PK profiles for the fixed-dose combination...
By Yahoo! Finance | 3 days ago -
Atea Pharmaceuticals Inc (AVIR) Q2 2024 Earnings Call Highlights: Strong Financial Position and ...
Atea executives discuss payer dynamics for Hepatitis C, competition with Pfizer's Paxlovid, financial highlights, and updates on COVID-19 trials. The company maintains strong financials and strategic ...
By Yahoo! Finance | 1 month ago -
How long does COVID live on surfaces? Experts answer your coronavirus FAQs.
The new COVID-19 strains XEC and MV-1 are rapidly spreading worldwide. XEC, a variant of Omicron, is expected to become dominant. Transmission occurs mainly through respiratory particles, and preventi...
By USA Today | 1 month ago
